false 2020 Q3 0001705843 --12-31 1 P3Y 1 0.003 0.017 0.019 0.025 0.774 0.812 0.779 0.789 P6Y P10Y P6Y9M18D P10Y 0001705843 2020-01-01 2020-09-30 xbrli:shares 0001705843 2020-11-05 iso4217:USD 0001705843 2020-09-30 0001705843 2019-12-31 iso4217:USD xbrli:shares 0001705843 2020-07-01 2020-09-30 0001705843 2019-07-01 2019-09-30 0001705843 2019-01-01 2019-09-30 0001705843 us-gaap:CommonStockMember 2020-06-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001705843 us-gaap:TreasuryStockMember 2020-06-30 0001705843 us-gaap:RetainedEarningsMember 2020-06-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001705843 2020-06-30 0001705843 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001705843 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001705843 us-gaap:CommonStockMember 2020-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001705843 us-gaap:TreasuryStockMember 2020-09-30 0001705843 us-gaap:RetainedEarningsMember 2020-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001705843 us-gaap:CommonStockMember 2019-06-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001705843 us-gaap:TreasuryStockMember 2019-06-30 0001705843 us-gaap:RetainedEarningsMember 2019-06-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001705843 2019-06-30 0001705843 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001705843 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001705843 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001705843 us-gaap:CommonStockMember 2019-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001705843 us-gaap:TreasuryStockMember 2019-09-30 0001705843 us-gaap:RetainedEarningsMember 2019-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001705843 2019-09-30 0001705843 us-gaap:CommonStockMember 2019-12-31 0001705843 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001705843 us-gaap:TreasuryStockMember 2019-12-31 0001705843 us-gaap:RetainedEarningsMember 2019-12-31 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001705843 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001705843 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001705843 us-gaap:CommonStockMember 2018-12-31 0001705843 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001705843 us-gaap:TreasuryStockMember 2018-12-31 0001705843 us-gaap:RetainedEarningsMember 2018-12-31 0001705843 2018-12-31 0001705843 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001705843 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001705843 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001705843 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0001705843 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001705843 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001705843 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0001705843 us-gaap:FairValueInputsLevel1Member us-gaap:ShortTermInvestmentsMember 2020-09-30 0001705843 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember 2020-09-30 0001705843 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001705843 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001705843 us-gaap:CommodityContractMember 2020-09-30 0001705843 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember 2019-12-31 0001705843 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001705843 us-gaap:CommodityContractMember 2019-12-31 0001705843 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001705843 us-gaap:CommercialPaperMember 2020-09-30 0001705843 us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0001705843 us-gaap:CommodityContractMember 2020-01-01 2020-09-30 0001705843 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0001705843 us-gaap:SellingGeneralAndAdministrativeExpensesMember clxt:CellectisMember 2020-07-01 2020-09-30 0001705843 us-gaap:SellingGeneralAndAdministrativeExpensesMember clxt:CellectisMember 2019-07-01 2019-09-30 0001705843 us-gaap:SellingGeneralAndAdministrativeExpensesMember clxt:CellectisMember 2020-01-01 2020-09-30 0001705843 us-gaap:SellingGeneralAndAdministrativeExpensesMember clxt:CellectisMember 2019-01-01 2019-09-30 0001705843 clxt:CellectisMember 2020-09-30 0001705843 clxt:LicenseAndRoyaltyFeesMember clxt:CellectisMember 2020-01-01 2020-09-30 0001705843 clxt:TwoThousandSeventeenOmnibusPlanMember 2020-09-30 0001705843 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 xbrli:pure 0001705843 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-01-01 2020-09-30 0001705843 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-09-30 0001705843 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2019-01-01 2019-09-30 0001705843 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-01-01 2019-09-30 0001705843 clxt:TwoThousandSeventeenOmnibusPlanMember 2020-01-01 2020-09-30 0001705843 clxt:TwoThousandSeventeenOmnibusPlanMember srt:MinimumMember 2020-01-01 2020-09-30 0001705843 clxt:TwoThousandSeventeenOmnibusPlanMember srt:MaximumMember 2020-01-01 2020-09-30 0001705843 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001705843 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001705843 clxt:TwoThousandSeventeenOmnibusPlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001705843 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001705843 clxt:NonemployeeRestrictedStockUnitsMember clxt:CellectisMember 2020-07-01 2020-09-30 0001705843 clxt:NonemployeeRestrictedStockUnitsMember clxt:CellectisMember 2019-07-01 2019-09-30 0001705843 clxt:NonemployeeRestrictedStockUnitsMember clxt:CellectisMember 2020-01-01 2020-09-30 0001705843 clxt:NonemployeeRestrictedStockUnitsMember clxt:CellectisMember 2019-01-01 2019-09-30 0001705843 us-gaap:PerformanceSharesMember clxt:TwoThousandSeventeenOmnibusPlanMember 2019-06-01 2019-06-30 0001705843 us-gaap:PerformanceSharesMember clxt:ThreeExecutiveOfficersMember clxt:TwoThousandSeventeenOmnibusPlanMember 2019-06-30 0001705843 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember clxt:TwoThousandSeventeenOmnibusPlanMember 2019-06-01 2019-06-30 0001705843 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember clxt:TwoThousandSeventeenOmnibusPlanMember 2019-06-01 2019-06-30 0001705843 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember clxt:TwoThousandSeventeenOmnibusPlanMember 2019-06-01 2019-06-30 0001705843 us-gaap:PerformanceSharesMember 2020-07-01 2020-09-30 0001705843 us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0001705843 us-gaap:PerformanceSharesMember 2019-01-01 2019-09-30 0001705843 us-gaap:PerformanceSharesMember clxt:TwoThousandSeventeenOmnibusPlanMember 2020-09-30 0001705843 us-gaap:PerformanceSharesMember clxt:TwoThousandSeventeenOmnibusPlanMember 2020-01-01 2020-09-30 0001705843 us-gaap:EquipmentMember 2020-09-30 0001705843 clxt:GrowersMember 2020-09-30 0001705843 clxt:GrowersMember clxt:ExtendedPaymentTermsMember 2020-09-30 0001705843 clxt:GrowersMember clxt:ExtendedPaymentTermsMember 2019-12-31 0001705843 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001705843 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001705843 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001705843 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001705843 clxt:SellingAndSupplyChainExpenseMember 2020-07-01 2020-09-30 0001705843 clxt:SellingAndSupplyChainExpenseMember 2019-07-01 2019-09-30 0001705843 clxt:SellingAndSupplyChainExpenseMember 2020-01-01 2020-09-30 0001705843 clxt:SellingAndSupplyChainExpenseMember 2019-01-01 2019-09-30 0001705843 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001705843 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001705843 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001705843 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 clxt:Segment 0001705843 clxt:PaycheckProtectionProgramLoanCARESActMember 2020-04-19 0001705843 clxt:PaycheckProtectionProgramLoanCARESActMember 2020-04-19 2020-04-19 0001705843 clxt:PaycheckProtectionProgramLoanCARESActMember 2020-01-01 2020-09-30 0001705843 clxt:SoybeanProductsMember 2020-07-01 2020-09-30 0001705843 clxt:SoybeanProductsMember clxt:EmployeeSeveranceAndOtherRelatedPaymentsMember srt:MaximumMember 2020-09-30 0001705843 clxt:SoybeanProductsMember clxt:TransitionalExpensesMember 2020-09-30 0001705843 clxt:SoybeanProductsMember 2020-09-30 0001705843 us-gaap:SubsequentEventMember 2020-10-20 2020-10-20

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020;

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                     to

Commission file number 001-38161

 

 

Calyxt, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

27-1967997

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

 

2800 Mount Ridge Road

 

 

Roseville, MN

 

55113-1127

(Address of principal executive offices)

 

(Zip Code)

 

(651) 683-2807

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange on which

registered

Common Stock (0.0001 par value)

  

CLXT

  

The NASDAQ Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

  

  

Accelerated filer

  

 

 

 

 

 

 

 

Non-accelerated filer

  

  

Smaller reporting company

  

 

 

 

 

 

 

 

 

  

 

  

Emerging growth company

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 5, 2020, there were 37,065,044 shares of common stock, $0.0001 par value per share, outstanding.

 

 


Table of Contents

 

 

 

 

 

 

 

 

PART I. FINANCIAL INFORMATION

 

4

 

 

 

 

 

Item 1. Consolidated Financial Statements

 

4

 

 

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

 

 

 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

31

 

 

 

 

 

Item 4. Controls and Procedures

 

31

 

 

 

 

 

PART II. OTHER INFORMATION

 

32

 

 

 

 

 

Item 1. Legal Proceedings

 

32

 

 

 

 

 

Item 1A. Risk Factors

 

32

 

 

 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

33

 

 

 

 

 

Item 6. Exhibits

 

34

 

 

 

 

 

SIGNATURE

 

35

 

 

 

 

 


Table of Contents

Terms

When we use the terms “we,” “us,” the “Company,” or “our” in this report, unless the context otherwise requires, we are referring to Calyxt, Inc. When we use the term “Cellectis,” we are referring to Cellectis S.A., our majority stockholder. Cellectis is a clinical-stage biotechnological company, employing its core proprietary technologies to develop best-in-class products in the field of immune-oncology.

We own the names and trademarks for Calyxt® and Calyno®; we also own or license other trademarks, trade names and service marks of Calyxt appearing in this Quarterly Report on Form 10-Q. The name and trademark Cellectis® and TALEN®, and other trademarks, trade names and service marks of Cellectis appearing in this Quarterly Report are the property of Cellectis. This Quarterly Report also contains additional trade names, trademarks and service marks belonging to other companies. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). We may also make forward-looking statements in other reports filed with the Securities and Exchange Commission, in materials delivered to stockholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements.

We have made these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “targets,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “projects,” “should,” or “will,” the negative of these terms and other similar terminology. Forward-looking statements in this report include statements about the potential impact of the COVID-19 pandemic on our business and operating results; our future financial performance; product pipeline and development; our business model and strategies for commercialization and sales of commercial products; regulatory progression; potential collaborations, partnerships and licensing arrangements and their contribution to our financial results, cash usage, and growth strategies; and anticipated trends in our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development, including unsuccessful field trials or developments trials or disruptions in seed production; the impact of improper handling of our product candidates by unaffiliated third parties during development, such as the improper aerial spraying of our high fiber wheat product candidate; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to make grain sales on terms acceptable to us; the timing of our grain sales; our ability to collect accounts receivable; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 5, 2020, (our Annual Report) and our subsequent reports on Forms 10-Q (including under the caption entitled “Risk Factors” in Part II, Item 1A of this Quarterly Report) and 8-K.

Any forward-looking statement made by us are based only on information currently available to us when, and speaks only as of the date, such statement is made. Except as required by securities and other applicable laws, we do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.

 

- 2 -


Table of Contents

Market Data

Unless otherwise indicated, information contained in this Quarterly Report concerning our industry and the markets in which we operate is based on information from various sources, including independent industry publications. In presenting this information, we have also made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in, the potential markets for our product. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled “Risk Factors” in our Annual Report and other subsequent reports on Forms 10-Q and 8-K filed with the SEC. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

Website Disclosure

We use our website (www.calyxt.com), our corporate Twitter account (@Calyxt_Inc) and our corporate LinkedIn account (https://www.linkedin.com/company/calyxt-inc) as routine channels of distribution of company information, including press releases, analyst presentations, and supplemental financial information, as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website and our corporate Twitter and LinkedIn accounts in addition to following press releases, filings with the SEC and public conference calls and webcasts.

Additionally, we provide notifications of announcements as part of our website. Investors and others can receive notifications of new press releases posted on our website by signing up for email alerts.

None of the information provided on our website, in our press releases or public conference calls and webcasts or through social media is incorporated into, or deemed to be a part of, this Quarterly Report or in any other report or document we file with the SEC, and any references to our website or our corporate Twitter and LinkedIn accounts are intended to be inactive textual references only.

- 3 -


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CALYXT, INC.

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Par Value and Share Amounts)

 

 

September 30, 2020

(unaudited)

 

 

December 31,

2019

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

7,170

 

 

$

58,610

 

Short-term investments

 

20,802

 

 

 

 

Restricted cash

 

393

 

 

 

388

 

Accounts receivable

 

2,432

 

 

 

1,122

 

Due from related parties

 

2

 

 

 

 

Inventory

 

5,953

 

 

 

2,594

 

Prepaid expenses and other current assets

 

1,515

 

 

 

808

 

Total current assets

 

38,267

 

 

 

63,522

 

Non-current restricted cash

 

1,041

 

 

 

1,040

 

Land, buildings, and equipment

 

22,823

 

 

 

23,212

 

Other non-current assets

 

347

 

 

 

324

 

Total assets

$

62,478

 

 

$

88,098

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

1,163

 

 

$

1,077

 

Accrued expenses

 

4,261

 

 

 

2,544

 

Accrued compensation

 

1,609

 

 

 

2,181

 

Due to related parties

 

481

 

 

 

977

 

Current portion of financing lease obligations

 

361

 

 

 

356

 

Other current liabilities

 

44

 

 

 

61

 

Total current liabilities

 

7,919

 

 

 

7,196

 

Financing lease obligations

 

18,022

 

 

 

18,244

 

Long-term debt

 

1,518

 

 

 

 

Other non-current liabilities

 

123

 

 

 

150

 

Total liabilities

 

27,582

 

 

 

25,590

 

Stockholders’ equity:

 

 

 

 

 

 

 

Common stock, $0.0001 par value; 275,000,000 shares authorized; 33,343,313 shares issued and 33,243,161 shares outstanding as of September 30, 2020, and 33,033,689 shares issued and 32,951,329 shares outstanding as of December 31, 2019

 

3

 

 

 

3

 

Additional paid-in capital

 

189,437

 

 

 

185,588

 

Common stock in treasury, at cost; 100,152 shares as of September 30, 2020, and 82,360 shares as of December 31, 2019

 

(1,043

)

 

 

(1,043

)

Accumulated deficit

 

(153,498

)

 

 

(122,057

)

Accumulated other comprehensive income (loss)

 

(3

)

 

 

17

 

Total stockholders’ equity

 

34,896

 

 

 

62,508

 

Total liabilities and stockholders’ equity

$

62,478

 

 

$

88,098

 

 

See accompanying notes to these consolidated financial statements.

- 4 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited and in Thousands Except Shares and Per Share Amounts)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2020

 

 

2019

 

2020

 

 

2019

 

Revenue

$

5,241

 

 

$

2,967

 

$

9,925

 

 

$

3,533

 

Cost of goods sold

 

7,060

 

 

 

3,528

 

 

16,265

 

 

 

3,865

 

Gross margin

 

(1,819

)

 

 

(561

)

 

(6,340

)

 

 

(332

)

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

2,204

 

 

 

3,579

 

 

7,816

 

 

 

8,536

 

Selling and supply chain

 

439

 

 

 

1,314

 

 

3,368

 

 

 

3,421

 

General and administrative

 

4,185

 

 

 

4,934

 

 

12,713

 

 

 

14,302

 

Management fees

 

68

 

 

 

305

 

 

172

 

 

 

1,117

 

Restructuring costs

436

 

 

 

 

 

436

 

 

 

 

Total operating expenses

 

7,332

 

 

 

10,132

 

 

24,505

 

 

 

27,376

 

Loss from operations

 

(9,151

)

 

 

(10,693

)

 

(30,845

)

 

 

(27,708

)

Interest, net

 

(324

)

 

 

32

 

 

(568

)

 

 

296

 

Foreign currency transaction loss

 

(1

)

 

 

(8

)

 

(28

)

 

 

(35

)

Loss before income taxes

 

(9,476

)

 

 

(10,669

)

 

(31,441

)

 

 

(27,447

)

Income taxes

 

 

 

 

 

 

 

 

 

 

Net loss

$

(9,476

)

 

$

(10,669

)

$

(31,441

)

 

$

(27,447

)

Basic and diluted net loss per share

$

(0.29

)

 

$

(0.32

)

$

(0.95

)

 

$

(0.84

)

Weighted average shares outstanding - basic and diluted

 

33,200,289

 

 

 

32,866,467

 

 

33,076,376

 

 

 

32,759,194

 

 

See accompanying notes to these consolidated financial statements.

- 5 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited and in Thousands Except Shares Outstanding)

 

Three months ended

September 30, 2020

 

Shares

Outstanding

 

 

Common

Stock

 

 

Additional

Paid-In

Capital

 

 

Shares

in

Treasury

 

 

Accumulated

Deficit

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

Total

Stockholders’

Equity

 

Balance at June 30, 2020

 

 

33,040,520

 

 

$

3

 

 

$

188,656

 

 

$

(1,043

)

 

$

(144,022

)

 

$

(41

)

 

$

43,553

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,476

)

 

 

 

 

 

(9,476

)

Stock based compensation

 

 

202,641

 

 

 

 

 

 

570

 

 

 

 

 

 

 

 

 

 

 

 

570

 

Issuance of common stock

 

 

 

 

 

 

 

 

211

 

 

 

 

 

 

 

 

 

 

 

 

211

 

Shares withheld for net share settlement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

38

 

 

 

38

 

Balance at September 30, 2020

 

 

33,243,161

 

 

$

3

 

 

$

189,437

 

 

$

(1,043

)

 

$

(153,498

)

 

$

(3

)

 

$

34,896

 

Three months ended

September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2019

 

 

32,859,700

 

 

$

3

 

 

$

180,237

 

 

$

(789

)

 

$

(99,223

)

 

$

(38

)

 

$

80,190

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,669

)

 

 

 

 

 

(10,669

)

Stock based compensation

 

 

7,713

 

 

 

 

 

 

2,705

 

 

 

 

 

 

 

 

 

 

 

 

2,705

 

Issuance of common stock

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

 

 

 

6

 

Shares withheld for net share settlement

 

 

 

 

 

 

 

 

 

 

 

(86

)

 

 

 

 

 

 

 

 

(86

)

Other comprehensive (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(17

)

 

 

(17

)

Balance at September 30, 2019

 

 

32,867,413

 

 

$

3

 

 

$

182,948

 

 

$

(875

)

 

$

(109,892

)

 

$

(55

)

 

$

72,129

 

Nine months ended

September 30, 2020

 

Shares

Outstanding

 

 

Common

Stock

 

 

Additional

Paid-In

Capital

 

 

Shares

in

Treasury

 

 

Accumulated

Deficit

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

Total

Stockholders’

Equity

 

Balance at December 31, 2019

 

 

32,951,329

 

 

$

3

 

 

$

185,588

 

 

$

(1,043

)

 

$

(122,057

)

 

$

17

 

 

$

62,508

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(31,441

)

 

 

 

 

 

(31,441

)

Stock based compensation

 

 

309,624

 

 

 

 

 

 

3,638

 

 

 

 

 

 

 

 

 

 

 

 

3,638

 

Issuance of common stock

 

 

 

 

 

 

 

 

211

 

 

 

 

 

 

 

 

 

 

 

 

211

 

Shares withheld for net share settlement

 

 

(17,792

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

(20

)

Balance at September 30, 2020

 

 

33,243,161

 

 

$

3

 

 

$

189,437

 

 

$

(1,043

)

 

$

(153,498

)

 

$

(3

)

 

$

34,896

 

Nine months ended

September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

 

32,648,893

 

 

$

3

 

 

$

176,069

 

 

$

(230

)

 

$

(82,445

)

 

$

 

 

$

93,397

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(27,447

)

 

 

 

 

 

(27,447

)

Stock based compensation

 

 

261,883

 

 

 

 

 

 

6,565

 

 

 

 

 

 

 

 

 

 

 

 

6,565

 

Issuance of common stock

 

 

 

 

 

 

 

 

314

 

 

 

 

 

 

 

 

 

 

 

 

314

 

Shares withheld for net share settlement

 

 

(43,363

)

 

 

 

 

 

 

 

 

(645

)

 

 

 

 

 

 

 

 

(645

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(55

)

 

 

(55

)

Balance at September 30, 2019

 

 

32,867,413

 

 

$

3

 

 

$

182,948

 

 

$

(875

)

 

$

(109,892

)

 

$

(55

)

 

$

72,129

 

 

See accompanying notes to these consolidated financial statements.

- 6 -


Table of Contents

CALYXT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited and in Thousands)

 

 

Nine Months Ended September 30,

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

Net loss

$

(31,441

)

 

$

(27,447

)

Adjustments to reconcile net loss to net cash used by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

1,372

 

 

 

1,051

 

Stock-based compensation

 

3,638

 

 

 

6,565

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(1,310

)

 

 

(1,304

)

Due to/from related parties

 

(498

)

 

 

(1,223

)

Inventory

 

(3,359

)

 

 

(2,371

)

Prepaid expenses and other current assets

 

(707

)

 

 

192

 

Accounts payable

 

86

 

 

 

127

 

Accrued expenses

 

1,717

 

 

 

(49

)

Accrued compensation

 

(572

)

 

 

478

 

Other current liabilities

 

(64

)

 

 

(743

)

Other non-current assets

 

140

 

 

 

36

 

Net cash used by operating activities

 

(30,998

)

 

 

(24,688

)

Investing activities

 

 

 

 

 

 

 

Purchases of land, buildings, and equipment

 

(1,146

)

 

 

(2,538

)

Short-term investments

 

(20,802

)

 

 

 

Net cash used by investing activities

 

(21,948

)

 

 

(2,538

)

Financing activities

 

 

 

 

 

 

 

Proceeds from Payroll Protection Program loan

 

1,518

 

 

 

 

Repayments of financing lease obligations

 

(217

)

 

 

(195

)

Proceeds from the exercise of stock options

 

211

 

 

 

314

 

Costs incurred related to shares withheld for net share settlement

 

 

 

 

(645

)

Proceeds from the sale and leaseback of land, buildings, and equipment

 

 

 

 

414

 

Net cash provided (used) by financing activities

 

1,512

 

 

 

(112

)

Net decrease in cash, cash equivalents and restricted cash

 

(51,434

)

 

 

(27,338

)

Cash, cash equivalents and restricted cash - beginning of period

 

60,038

 

 

 

95,288

 

Cash, cash equivalents and restricted cash – end of period

$

8,604

 

 

$

67,950

 

 

See accompanying notes to these consolidated financial statements.

- 7 -


Table of Contents

 

CALYXT, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Our unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In our opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates.

Certain prior year amounts have been reclassified to conform to the current year presentation.

For further information, refer to the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 5, 2020. The accompanying Balance Sheet as of December 31, 2019, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2019.

Short-term investments

We consider investments with more than ninety days to maturity at issuance to be short-term investments. These short-term investments are considered trading securities and are carried at fair value with any unrealized gains and losses recorded in current earnings as a component of interest, net.

Revenue Recognition

In certain instances, we may sell grain to a processor with a commitment to repurchase any soybean meal resulting from their grain crushing activity with a single net cash settlement occurring between the parties. In those instances, we recognize revenue from the sale of grain in the amount of the final net cash settlement with the processor. We also recognize revenue on our sale of the meal to our customers in accordance with our previously disclosed revenue recognition accounting policies. Costs are ascribed to grain and meal sold pursuant to the agreement with the processor.

 

2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE, HEDGING ACTIVITIES, AND CONCENTRATIONS OF CREDIT RISK

Financial Instruments Measured at Fair Value and Financial Statement Presentation

Financial instruments including cash and cash equivalents, restricted cash, due from related parties, accounts payable, due to related parties and all other current liabilities have carrying values that approximate fair value. We measure short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows:

Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities.

Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Fair values are based on at least one significant unobservable input for the asset or liability.

- 8 -


Table of Contents

Fair Value Measurements and Financial Statement Presentation

The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of September 30, 2020, and December 31, 2019, were as follows:

 

 

September 30, 2020

 

September 30, 2020

 

 

Fair Values of Assets

 

Fair Values of Liabilities

 

In Thousands

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Other items reported at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments

$

20,802

 

 

$

 

 

$

 

 

$

20,802

 

$

 

 

$

 

 

$

 

 

$

 

Commodity derivative contracts

 

132

 

 

 

 

 

 

 

 

 

132

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

20,934

 

 

$

 

 

$

 

 

$

20,934

 

$

 

 

$

 

 

$

 

 

$

 

 

 

December 31, 2019

 

December 31, 2019

 

 

Fair Values of Assets

 

Fair Values of Liabilities

 

In Thousands

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Other items reported at fair value: